PFE vs ABBV
PFE 与 ABBV 的估值与基本面并排对比(公开数据)。
关键统计
| 指标 | PFEPfizer Inc. | ABBVAbbVie Inc. |
|---|---|---|
| 市值 | $144.02B | $470.10B |
| 市盈率(TTM) | 19.3 | 131.1 |
| 市净率 | 1.60 | — |
| 市销率 | 2.3x | 7.6x |
| 股息率 | 6.78% | 2.48% |
| 营收 | $63.31B(TTM) | $61.16B(TTM) |
| 营收同比增长 | -1.6% | 8.6% |
| 净利润 | $7.49B(TTM) | $3.63B(TTM) |
| 净利同比增长 | -3.2% | -1.2% |
| 每股收益(稀释) | $1.31(TTM) | $2.03(TTM) |
| 息税前利润率 | 16.3% | 24.6% |
| 净资产收益率 | 8.6% | — |
| 投入资本回报率 | 6.7% | 20.0% |
| 一年总回报 | +11.0% | +41.0% |
数据来自 SEC 文件 · 仅供参考 · 非投资建议
1 万美元的成长:PFE vs ABBV
| 指标 | PFE | ABBV |
|---|---|---|
| 期末价值 | $13.6K | $72.8K |
| 总回报 | +36.0% | +628.0% |
| 年化收益 (CAGR) | +3.0% | +21.2% |
| 波动率 | 23.9% | 25.8% |
| 夏普比率 | 0.08 | 0.73 |
| 索提诺比率 | 0.12 | 1.01 |
| 最大回撤 | -59.0% | -45.1% |
基于 2600 个共同交易日,2016-03-28 → 2026-07-29 · 无风险利率 3.9%(当前短端国债,全程恒定)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
相关对比
数据延迟 · 公开数据 · 仅供参考 · 非投资建议(本页不评判孰优孰劣)